Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Company issues update on lapatinib
June 23rd, 2005
Thirty-five percent of women (14 of 40) with locally advanced or metastatic breast cancer have responded to lapatinib as first-line therapy, according to interim results of a study reported at the annual meeting of the American Society of Clinical Oncology (ASCO). The data are the first to be reported on the use of lapatinib as a first-line therapy. Lapatinib is an oral therapy targeting intracellular components of a receptor known as ErbB2 and a second receptor, Erbb1, which have been implicated in the growth of various tumor types. The phase II trial (EGF 20009) tests lapatinib as first-line therapy for breast-cancer patients with tumors that...
Source: Women's Health Weekly (2005-06-23)
|
